Tags

Type your tag names separated by a space and hit enter

DEVELOPMENT OF SOLID LIPID NANOCARRIERS FOR ORAL DELIVERY OF CANDESERTAN CILEXETIL.
Acta Pol Pharm. 2016 Nov; 73(6):1631-1638.AP

Abstract

Candesertan cilexetil is a Biopharmaceutics Classification System (BCS) Class II drug possessing high permeability but low aqueous solubility; hence its oral bioavailability is limited in terms of the solubility rate. The aim of this research was to develop solid lipid nanopa rticle (SLN) drug delivery systems of candesertan cilexetil to enhance its aqueous solubility, thereby improving the oral bioavailability of the drug. SLN formulations were produced using a combined technique of high shear homogenization and ultrasonication method. Drug/lipid and surfactant/co-surfactant ratios of the candesertan cilexetil loaded SLNs were investigated based on various final characteristics of the nanocarriers; namely, encapsulation efficiency, average particle diameter, size distribution, surface charge, thermal behavior, and in vitro drug release profiles. Lipid based nanocarriers of candesertan cilexetil displayed spherical particles having a nanometer size. High encapsulation efficiencies were obtained due to the high lipid solubility of the drug. DSC analysis demonstrated the transformation of the crystalline structure of candesertan cilexetil to amorphous form into the SLN formulations and there was no interaction between the drug and the excipients. Consequently, the oral delivery of candesertan cilexetil with the design of Compritol® 888 ATO based lipid nanocarriers may lead to an increase in bioavailability of the drug and thus, more effective therapy may be obtained.

Authors

No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

29634119

Citation

Ugurlu, Timucin, et al. "DEVELOPMENT of SOLID LIPID NANOCARRIERS for ORAL DELIVERY of CANDESERTAN CILEXETIL." Acta Poloniae Pharmaceutica, vol. 73, no. 6, 2016, pp. 1631-1638.
Ugurlu T, Nalbantoglu A, Sengel-Turk CT. DEVELOPMENT OF SOLID LIPID NANOCARRIERS FOR ORAL DELIVERY OF CANDESERTAN CILEXETIL. Acta Pol Pharm. 2016;73(6):1631-1638.
Ugurlu, T., Nalbantoglu, A., & Sengel-Turk, C. T. (2016). DEVELOPMENT OF SOLID LIPID NANOCARRIERS FOR ORAL DELIVERY OF CANDESERTAN CILEXETIL. Acta Poloniae Pharmaceutica, 73(6), 1631-1638.
Ugurlu T, Nalbantoglu A, Sengel-Turk CT. DEVELOPMENT of SOLID LIPID NANOCARRIERS for ORAL DELIVERY of CANDESERTAN CILEXETIL. Acta Pol Pharm. 2016;73(6):1631-1638. PubMed PMID: 29634119.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - DEVELOPMENT OF SOLID LIPID NANOCARRIERS FOR ORAL DELIVERY OF CANDESERTAN CILEXETIL. AU - Ugurlu,Timucin, AU - Nalbantoglu,Aysun, AU - Sengel-Turk,Ceyda Tuba, PY - 2018/4/11/entrez PY - 2016/11/1/pubmed PY - 2018/5/4/medline SP - 1631 EP - 1638 JF - Acta poloniae pharmaceutica JO - Acta Pol Pharm VL - 73 IS - 6 N2 - Candesertan cilexetil is a Biopharmaceutics Classification System (BCS) Class II drug possessing high permeability but low aqueous solubility; hence its oral bioavailability is limited in terms of the solubility rate. The aim of this research was to develop solid lipid nanopa rticle (SLN) drug delivery systems of candesertan cilexetil to enhance its aqueous solubility, thereby improving the oral bioavailability of the drug. SLN formulations were produced using a combined technique of high shear homogenization and ultrasonication method. Drug/lipid and surfactant/co-surfactant ratios of the candesertan cilexetil loaded SLNs were investigated based on various final characteristics of the nanocarriers; namely, encapsulation efficiency, average particle diameter, size distribution, surface charge, thermal behavior, and in vitro drug release profiles. Lipid based nanocarriers of candesertan cilexetil displayed spherical particles having a nanometer size. High encapsulation efficiencies were obtained due to the high lipid solubility of the drug. DSC analysis demonstrated the transformation of the crystalline structure of candesertan cilexetil to amorphous form into the SLN formulations and there was no interaction between the drug and the excipients. Consequently, the oral delivery of candesertan cilexetil with the design of Compritol® 888 ATO based lipid nanocarriers may lead to an increase in bioavailability of the drug and thus, more effective therapy may be obtained. SN - 0001-6837 UR - https://www.unboundmedicine.com/medline/citation/29634119/DEVELOPMENT_OF_SOLID_LIPID_NANOCARRIERS_FOR_ORAL_DELIVERY_OF_CANDESERTAN_CILEXETIL_ DB - PRIME DP - Unbound Medicine ER -